上海市某医院血液肿瘤康复儿童疫苗接种可行性评估体系的临床实证分析

职业与健康 ›› 2025, Vol. 41 ›› Issue (8): 1050-1054.

上海市某医院血液肿瘤康复儿童疫苗接种可行性评估体系的临床实证分析

杨丹丹¹, 刘文敏¹, 杨来宝¹, 薛曹怡¹, 高怡瑾², 邓鹏飞¹

1.上海市浦东新区疾病预防控制中心免疫预防科,复旦大学浦东预防医学研究院,上海 200136;
2.上海交通大学医学院附属上海儿童医学中心血液肿瘤科,上海 200127

收稿日期:2024-06-27 修回日期:2024-07-30 出版日期:2025-04-15 发布日期:2025-12-18
通信作者: 邓鹏飞,主管医师,E-mail：masterdpf@163.com
作者简介:杨丹丹,女,主管医师,主要从事免疫规划工作。
基金资助:
上海市浦东新区卫生健康委员会重点学科-免疫预防学（PWZxk2022-25）; 上海市优青项目（GWV-10.2-YQ38）; 上海市加强公共卫生体系建设三年行动计划（2023—2025年）优秀学科带头人（GWVI-11.2-XD08）; 上海市浦东新区卫生健康委员会学科带头人培养计划（PWRd2020-14）; 上海市浦东新区科技发展基金项目（PKJ2023-Y34）; 上海市浦东新区雄鹰人才（PDCDC-XY-2024-09）

Clinical verifications of feasibility evaluation system for vaccination in convalescent children with hematologic malignancies in a hospital in Shanghai

YANG Dandan¹, LIU Wenmin¹, YANG Laibao¹, XUE Caoyi¹, GAO Yijin², DENG Pengfei¹

1. Department of Immunology and Prevention,Shanghai Pudong District Center for Diseases Control and Prevention,Fudan University Pudong Institute of Preventive Medicine,Shanghai 200136,China;
2. Department of Hematology and Oncology,Shanghai Children's Medical Center Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai 200127,China

Received:2024-06-27 Revised:2024-07-30 Online:2025-04-15 Published:2025-12-18
Contact: DENG Pengfei,Physician in charge,E-mail：masterdpf@163.com

摘要/Abstract

摘要： 目的分析血液肿瘤康复儿童疫苗接种可行性评估体系的临床实证,为血液肿瘤康复儿童疫苗接种提供参考依据。方法采用改良德尔菲法和层次分析法构建血液肿瘤康复儿童疫苗接种可行性评估体系,并随机抽取2022年12月—2023年7月上海儿童医学门诊疫苗评估门诊就诊的血液肿瘤康复儿童开展临床实证,分析临床医务人员评估意见和疫苗接种可行性评估体系的一致性。结果经过两轮德尔菲专家咨询,两轮专家权威程度（Cr）均≥0.70,专家积极系数均为100.00%,专家意见协调性较好（P<0.01）;最终确定疫苗接种可行性评估体系指标共56条,包括3个维度（临床检验、生理学及基础信息指标和疾病恢复状况）、15个方面、38个指标,3个维度归一化权重系数分别为0.405、0.114、0.481。随机抽取106名疫苗评估门诊就诊的血液肿瘤康复儿童进行临床实证,疫苗接种可行性评估体系的整体信度（Cronbach's α=0.840）、效度（CVI=0.829、KMO=0.839）较高,其中76名儿童经临床医务人员评估后推荐进行疫苗接种,有78名儿童经疫苗接种可行性评估体系评估后推荐进行疫苗接种,两者一致性检验较强（Kappa=0.858,P<0.01）。结论血液肿瘤康复儿童疫苗接种可行性评估体系的内容较为完善,临床实证效果较好,可为血液肿瘤康复儿童疫苗接种评估提供思路和参考。

关键词: 血液肿瘤, 儿童, 疫苗接种, 评估

Abstract: Objective To analyze the clinical verifications of the feasibility evaluation system for vaccination of convalescent children with hematologic malignancies,and provide reference for vaccination of convalescent children with hematologic malignancies. Methods A modified Delphi and analytic hierarchy process were used to construct a feasibility evaluation system for vaccination of convalescent children with hematologic malignancies. Clinical demonstration was carried out by randomly select convalescent children with hematologic malignancies who visited the vaccine evaluation clinic of Shanghai Children's Medical Center from December 2022 to July 2023. The consistency between the evaluation opinions of clinical medical staff and the feasibility evaluation system for vaccination was analyzed. Results After two rounds of Delphi expert consultation,the expert authority degree（Cr） in both rounds was ≥0.70,the positive coefficient of experts was 100%,and the consistency of expert opinions was good（P<0.01）.The final determination of the feasibility evaluation system for vaccination includes 56 items,including 3 dimensions（clinical laboratory,physiological and basic information indicators,and disease recovery status）,15 aspects and 38 indicators,and the normalized weight coefficients of the 3 dimensions were 0.405,0.114 and 0.481,respectively.A total of 106 convalescent children with hematologic malignancies who visited the vaccine evaluation clinic were randomly selected for clinical verification,the overall reliability（Cronbach's α=0.840） and validity（CVI=0.829,KMO=0.839） of the vaccination feasibility evaluation system were high. Among them,76 children were recommended for vaccination after evaluation by clinical medical personnel,and 78 children were recommended for vaccination after evaluation by the vaccine feasibility evaluation system. The consistency test between the two was strong（Kappa=0.858,P<0.01）. Conclusion The feasibility evaluation system of vaccination in convalescent children with hematologic malignancies by modified Delphi Method is relatively complete,and preliminary clinical evidence was good,which can provide new ideas and reference for the vaccination evaluation in convalescent children with hematologic malignancies.

Key words: Hematologic malignancies, Children, Vaccination, Evaluation

中图分类号:

R186

杨丹丹, 刘文敏, 杨来宝, 薛曹怡, 高怡瑾, 邓鹏飞. 上海市某医院血液肿瘤康复儿童疫苗接种可行性评估体系的临床实证分析. [J]职业与健康, 2025, 41(8): 1050-1054.

YANG Dandan, LIU Wenmin, YANG Laibao, XUE Caoyi, GAO Yijin, DENG Pengfei. Clinical verifications of feasibility evaluation system for vaccination in convalescent children with hematologic malignancies in a hospital in Shanghai. [J]OCCUPATION AND HEALTH, 2025, 41(8): 1050-1054.

参考文献

[1] PULTE D,GONDOS A,BRENNER H.Trends in survival after diagnosis with hematologic malignancy in adolescence or young adulthood in the United States,1981-2005[J].Cancer,2009,115(21):4973-4979.
[2] PULTE D,GONDOS A,BRENNER H.Trends in 5-and 10-year Survival After Diagnosis with Childhood Hematologic Malignancies in the United States,1990-2004[J].JNCI,2008,100(18):1301-1309.
[3] NEAGA A,JIMBU L,MESAROS O,et al.Why do children with acute lymphoblastic leukemia fare better than adults?[J].Cancers(Basel),2021,13(15):3886.
[4] PULTE D,JANSEN L,BRENNER H.Changes in long term survival after diagnosis with common hematologic malignancies in the early 21st century[J].Blood cancer journal(New York),2020,10(5):56.
[5] DENG P,YANG T,ZHANG H,et al.Prospective clinical trial of hepatitis B vaccination for children with hematological malignancies:a study on the safety and immunogenicity efficacy[J].Hum Vaccin Immunother,2021,17(11):4578-4586.
[6] 韩英,胡丹丹,韦茹,等.广东省特需人群接种门诊特殊健康状态儿童预防接种探索[J].中国疫苗和免疫,2021,27(6):678-683.
[7] PIETRAS W,CHABER R,PELA H,et al.The recovery of immune system parameters in children following lymphoblastic leukemia therapy- preliminary report[J].Adv Clin Exp Med,2014,23(1):97-102.
[8] WU C,WU P,LI P,et al.Construction of an index system of core competence assessment for infectious disease specialist nurse in China:a Delphi study[J].BMC Infectious Diseases,2021,21(1):791.
[9] BAI X,GAN X,YANG R,et al.Construction of a competency evaluation index system for front-line nurses during the outbreak of major infectious diseases:A Delphi study[J].PLoS One,2022,17(7):e270902.
[10] Q L.A novel Likert scale based on fuzzy sets theory[J].Expert Syst Appl,2013,5(40):1609-1618.
[11] SATTY A M H.A review of Methods for handling missing data in the form of dropouts in longitudinal clinical trials[J].BOPAMS,2014, 3(2):2310-2331.
[12] 刘伟涛,顾鸿,李春洪.基于德尔菲法的专家评估方法[J].计算机工程,2011,37(S1):189-191.
[13] 柯雄,陈英耀,胡献之,等.公立医疗机构公益性指标赋权中的方法比较与权重优化[J].中国卫生经济,2013,32(8):68-70.
[14] 龙耀,周璇,邓鹏飞,等.基于改良德尔菲法的健康人生理性衰老量表构建[J].中南大学学报(医学版),2016,41(4):422-426.
[15] 平卫伟. Delphi法的研究进展及其在医学中的应用[J].疾病控制杂志,2003,7(3):243-246.
[16] 朱梦,龚磊,宋丹丹,等.应用德尔菲法构建流感与新型流感暴发早期预警指标体系[J].安徽医科大学学报,2018,53(9):1403-1406.
[17] 常骁毅,白婷,段雨超,等.基于德尔菲法与层次分析法构建大型医用设备维修保养服务评价体系的研究[J].中国医学装备,2020,17(7):122-127.
[18] HOFMANN G,ZIERK J,SOBIK B,et al.Temporal evolution and differential patterns of cellular reconstitution after therapy for childhood cancers[J].Sci Rep,2023,13(1):4022.
[19] WILLIAMS A P,BATE J,BROOKS R,et al.Immune reconstitution in children following chemotherapy for acute leukemia[J].eJHaem,2020,1(1):142-151.
[20] KOVACS G T,BARANY O,SCHLICK B,et al.Late immune recovery in children treated for malignant diseases[J].Pathol Oncol Res,2008,14(4):391-397.
[21] CESARO S,GIACCHINO M,FIOREDDA F,et al.Guidelines on vaccinations in paediatric haematology and oncology patients[J].Biomed Res Int,2014,2014:1-10.
[22] ZIGNOL M,PERACCHI M,TRIDELLO G,et al.Assessment of humoral immunity to poliomyelitis,tetanus,hepatitis B,measles,rubella,and mumps in children after chemotherapy[J].Cancer,2004,101(3):635-641.
[23] ONORATELI M,BOTANA C,PERALTA L,et al.Humoral immunity to tetanus,measles and rubella in children with acute lymphoblastic leukemia after chemotherapy[J].Arch Argent Pediatr,2016,114(6):549-552.